source
- FDA pauses public release of Complete Response Letters to limit litigation riskThe FDA announced it has temporarily halted the routine public posting of Complete Response Letters (CRLs), which are letters sent to drug sponsors when the agency does not approve a marketing appl…
- Ipsen's Dysport shows positive Phase 3 results in migraine, Tarsus acquires iRenix for $75MIpsen reported that its injectable neurotoxin Dysport met the primary endpoint in a Phase 3 trial aimed at reducing monthly migraine days. The trial demonstrated a statistically significant reduct…